Latest Conference Articles

November 1st 2014, 12:51pm

Annual Meeting of the American Thyroid Association

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

November 1st 2014, 12:25pm

Annual Meeting of the American Thyroid Association

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

November 1st 2014, 11:08am

Annual Meeting of the American Thyroid Association

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

November 1st 2014, 8:10am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

November 1st 2014, 7:59am

Chicago Multidisciplinary Symposium in Thoracic Oncology

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

November 1st 2014, 7:52am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

November 1st 2014, 7:31am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

November 1st 2014, 7:15am

Annual Meeting of the American Thyroid Association

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

October 31st 2014, 4:50pm

Annual Meeting of the American Thyroid Association

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

October 31st 2014, 4:17pm

Annual Meeting of the American Thyroid Association

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

October 31st 2014, 12:26pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

October 31st 2014, 11:41am

Annual Meeting of the American Thyroid Association

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

October 31st 2014, 11:23am

Annual Meeting of the American Thyroid Association

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

October 31st 2014, 10:32am

Annual Meeting of the American Thyroid Association

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

October 31st 2014, 8:14am

Chicago Multidisciplinary Symposium in Thoracic Oncology

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

October 31st 2014, 8:10am

Annual Meeting of the American Thyroid Association

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

October 31st 2014, 6:42am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

October 31st 2014, 6:32am

Annual Meeting of the American Thyroid Association

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

October 31st 2014, 6:32am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

October 31st 2014, 5:01am

Chicago Multidisciplinary Symposium in Thoracic Oncology

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.